Ruthenium(II) Complexes for Nucleic Acid Nuclear Targeting
Solution Overview
Problem
Current gene therapy methods using viral and non-viral vectors face limitations in efficiency and safety, and existing ruthenium complexes for gene delivery have large molecular weights and complex synthesis processes, with limited effectiveness and lack of targeting specificity to cell nuclei.
Innovation Solution
Development of ruthenium(II) complexes with specific auxiliary ligands that form stable coordination complexes with nucleic acids, facilitating their transport into viable cells and localization within cell nuclei, enhancing delivery efficiency and allowing for fluorescent tracking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors or traditional non-viral vectors are used for gene transfection, then therapeutic genes can be delivered into cells, but the efficiency and safety are limited and clinical uses are greatly restricted
Solution Approach 1:
The patent uses ruthenium(II) complexes as intermediary carriers to mediate the delivery of nucleic acids into cells. These complexes form stable coordination bonds with nucleic acids, protecting them during transport while enabling efficient cellular uptake and nuclear localization, thus resolving the contradiction between delivery efficiency and safety
Solution Approach 2:
The invention creates composite structures by combining ruthenium(II) complexes with nucleic acids to form ruthenium-nucleic acid coordination complexes. This composite material integrates the advantages of both components: the stability and targeting capability of ruthenium complexes with the therapeutic function of nucleic acids, achieving high efficiency and safety in gene delivery
2Reliability
If existing ruthenium complexes are used as gene vectors, then some gene delivery capability is achieved, but they have large molecular weights and complex synthesis processes with limited effectiveness
Solution Approach 1:
The patent optimizes key parameters of ruthenium complexes including molecular weight, ligand structure, and coordination geometry to enhance gene delivery effectiveness. By adjusting these parameters, the invention achieves smaller, more effective complexes with simpler synthesis routes compared to existing ruthenium gene vectors
Solution Approach 2:
The invention introduces specific functional groups and ligand structures at localized positions on the ruthenium complex to enhance nucleic acid binding affinity and cellular uptake. This localized optimization allows the complex to maintain simplicity while achieving superior gene delivery effectiveness
3Productivity
If gene delivery is performed without nuclear targeting, then nucleic acids can enter cells, but replication and transcription efficiency is limited because these processes occur in cell nucleuses
Solution Approach 1:
The ruthenium(II) complexes are designed with inherent nuclear targeting capabilities that enable them to guide nucleic acids to the cell nucleus before transcription and replication processes begin. This preliminary nuclear localization ensures that therapeutic genes are positioned in the correct cellular compartment for optimal expression
Solution Approach 2:
The patent utilizes the luminescent properties of ruthenium(II) complexes to track and visualize nuclear localization. The optical properties of these complexes allow researchers to monitor in real-time the transport of nucleic acids to the nucleus, providing a method to assess and optimize nuclear targeting efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ruthenium(II) complexes effectively change the morphology of nucleic acids to improve transmembrane transport and nuclear localization, enhancing gene therapy delivery and fluorescent tracking capabilities.
Implementation Method 1
ruthenium (II) complexes having the following general formula (I) may be effectively combined with nucleic acid sequence and may effectively change morphologies of long sequence (e.g., more than 50 bp) nucleic acids
Implementation Method 2
allowing for fluorescent tracking
Data Source
Figure 1~5
Figure 6~10B
Figure 11A~13B
AI summary
The present invention discloses an application of ruthenium complexes as nucleic acid vectors of target cell nucleuses. Experimental data shows that ruthenium (II) complexes may be effectively combined with nucleic acid sequence and may effectively change morphologies of long sequence nucleic acids to make the nucleic acids be effectively delivered into viable cells via transmembrane transport and be well located within cell nucleuses, thus greatly improving transport efficiency of the nucleic acids. Based on this property, nucleic acid sequences can be conveniently transported into cells for gene therapy or fluorescent tracking or the like. The method for preparing a ruthenium coordination complex-nucleic acid complex in accordance with the present invention may provide a stable ruthenium coordination complex-nucleic acid complex in a more efficient manner and may provide many better effects.